Skip to content

Transcatheter Microguidewire Drilling for Transseptal Left Atrial Access

Transcatheter Microguidewire Drilling (TMD) for Transseptal Left Atrial Access: First-in-human Use Study

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04561908
Acronym
TMD
Enrollment
100
Registered
2020-09-24
Start date
2020-09-04
Completion date
2022-12-01
Last updated
2022-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Septal Dilatation, Heart Diseases

Keywords

transseptal, puncture, microguidewire

Brief summary

This study aims to investigate the safety and efficacy of transcatheter microguidewire drilling (TMD) for transseptal left atrial access in patients with abnormal atrial septal morphology.

Detailed description

Despite the widespread application and decades of experience, Brockenbrough-needle transseptal puncture still risks cardiac perforations and secondary pericardial effusion/tamponade, especially in patients with abnormal atrial septal morphology. To facilitate atrial septal crossing, different methods and devices have been developed, including radiofrequency energy, excimer laser, SafeSept wire and so on. However, these are still limited by availability and cost, and the advantages might be further offset by the potential risks. In addition, these methods are performed mainly with the linear insertion technique, which might result in less forward-force to penetrate atrial septum and displacement of needle-tip. Therefore, it is necessary to develop a safe, available and low-cost transseptal procedure for these patients. Through a Brockenbrough needle, the hard back-end of the microguidewire (0.014-inch) has the potential to drill through the atrial septum with ease. Compared with a standard linear insertion technique, the penetration might be improved and less force is required with the bidirectional rotation technique, and the related risks might be reduced with the modified TSP due to the thin microguidewire. After the passage of the needle, the soft-end of microguidewire can be introduced into left pulmonary superior vein, which can become a safe rail for the introduction of puncture dilator/sheath. In this study, we examined the effectiveness and safety of microguidewire-assisted TSP for patients with complex atrial septum.

Interventions

DEVICETransseptal puncture with Brockenbrough-needle

Conventional transseptal puncture with Brockenbrough-needle

DEVICEMicroguidewire-assisted transseptal puncture

Microguidewire-assisted transseptal puncture (0.014-inch microguidewire)

Sponsors

China National Center for Cardiovascular Diseases
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Intervention model description

prospective, single-center, randomized, controlled study

Eligibility

Sex/Gender
ALL
Age
3 Years to 99 Years
Healthy volunteers
No

Inclusion criteria

1) Patients with atrial septal aneurysm (a bulging of the atrial septum of at least 10 mm beyond the plane of the atrial septum into either the right or left atrium); 2) Or patients with previous multiple transseptal punctures (≧2); 3) Or patients with thickened atrial septum (thickness ≧3 mm); 4) Or patients with enlarged right atrium (≧ 6 cm) and diminished left atrium (\< 3 cm); 5) Or patients with prior mitral valve surgery; 6) Or patients with atrial baffles.

Exclusion criteria

1) Associated atrial septal defect or patent foramen ovale; 2) Associated interrupted inferior vena cava; 3) Presence of implanted cardiac devices; 4) Echocardiographic evidence of intracardiac thrombus, mass, tumor or vegetation; 5) Thromboembolic events within the last 6 months; 6) Patients unable to grant informed, written consent.

Design outcomes

Primary

MeasureTime frameDescription
Procedural Success1 Day of procedureNumber of participants with successful transseptal left atrial access
Related-complications1 Day of procedurePericardial effusion

Secondary

MeasureTime frameDescription
Transseptal Access Procedure Time1 Day of procedureTotal amount of procedure time, from the beginning of the transseptal procedure until left atrium access is obtained in each patient.

Countries

China

Contacts

Primary ContactChaowu Yan, PhD and MD
chaowuyan@163.com+861088398408
Backup ContactShiguo Li, PhD and MD
sgli2000@hotmail.com+861088398408

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026